Results 61 to 70 of about 42,251 (222)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia

eJHaem, 2020
Optimizing the induction therapy of acute myeloid leukemia (AML) may improve the remission rate and reduce the risk of relapse, thereby extend survival. Cyclophosphamide (CTX) shows benefit in treating relapsed and refractory AML patients, but it has not
Qingguo Liu, Hongye Gao, Junfan Li, Yimin Hu, Lihua Wu, Xin Zhao, Shangzhu Li   +6 more
doaj   +1 more source

Role of CD19 and specific KIT‐D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities

Cancer Medicine, 2021
High‐dose cytarabine (Ara‐C) has been reported with increased treatment‐related mortality, whereas few data are available concerning intermediate‐dose Ara‐C for induction of acute myeloid leukemia (AML) with t(8;21) translocation.
Biao Wang, Bin Yang, Yun Ling, Jihong Zhang, Xiaoying Hua, Weiying Gu, Feng Yan   +6 more
doaj   +1 more source

Optical genome mapping detects cryptic high‐risk and targetable abnormalities in adult AML

British Journal of Haematology, EarlyView.
Summary Acute myeloid leukaemia (AML) risk stratification relies on cytogenetic and molecular abnormalities defined by European LeukemiaNet (ELN) 2022. Conventional cytogenetic techniques, including chromosomal banding analysis (CBA) and fluorescence in situ hybridization, have limited resolution and may miss cryptic events. Optical genome mapping (OGM)
Audrey Bidet, Elodie Laharanne, Manon Dos Santos, Anne‐Charlotte De Grande, Thibaut Leguay, Arnaud Pigneux, Eric Frison, Sandrine Achard, Stéphanie Dupont‐Moufakkir, Emilie Klein, Pierre‐Yves Dumas   +10 more
wiley   +1 more source

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival

British Journal of Haematology, EarlyView.
Summary Bridging therapy (BT) prior to brexucabtagene autoleucel (brexu‐cel) in mantle cell lymphoma (MCL) is supported by limited evidence. Here, we report BT modality and outcome in 176 patients at 15 centres in the United Kingdom. BT was delivered to 90% (158/176), the majority receiving standard chemotherapy +/− radiotherapy (53%) (SD chemo +/− RT)
Maeve A. O'Reilly, William Wilson, Bernard Maybury, Andrea Kuhnl, Claire Roddie, Ben Uttenthal, Rod Johnson, Rajesh Alajangi, Thomas Creasey, Ahmed Abdulgawad, Carlos Gonzalez Arias, Sunil Iyengar, Graeme Ferguson, Katerina Panopoulou, Alison Delaney, Angharad Pryce, Lourdes Rubio, Ceri Jones, Jonathan Lambert, Shweta Gupta, Amrith Mathew, Shenbagaram Kasivisvanathan, Olateni Awofisayo, Shreyas Hanmantgad, Graham P. Collins, Caroline Besley, Frances Seymour, Robin Sanderson, Sridhar Chaganti   +28 more
wiley   +1 more source

Efficacy and safety of stem cell mobilization with etoposide +cytarabine plus G-CSF in poor mobilizers with relapsed or refractory lymphoma

Frontiers in Immunology
BackgroundAutologous stem cell transplantation (ASCT) is a potentially curative strategy for relapse or refractory(r/r) aggressive lymphoma. However, a proportion of lymphoma patients who are at high risk of mobilization failure fail to mobilize stem ...
Zhijuan Zhu, Xiaofan Li, Xiaofan Li, Xiaohong Yuan, Xianling Chen, Ting Lin, Xiangli Guo, Nainong Li, Nainong Li   +8 more
doaj   +1 more source

Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real‐world study

British Journal of Haematology, EarlyView.
Summary Classical Hodgkin lymphoma (cHL) is the most frequent lymphoma in children, adolescents and young adults (CAYA). Despite therapeutic advances, around 15% of patients relapse or have refractory (R/R) disease. Conventional salvage regimens remain effective but are associated with substantial long‐term toxicity. Immune checkpoint inhibitors (CPIs),
Marlène Pouthier, Nathalie Garnier, Amaury Leruste, Charlotte Rigaud, Catherine Curtillet, Stéphane Ducassou, Marilyne Poirée, Marie‐Emilie Dourthe, Cécile Pochon, Marie‐Laure Couec, Jacinthe Bonneau‐Lagacherie, Françoise Montravers, Sabah Boudjemaa, Bénédicte Jonca, Stéphanie Haouy, Thierry Leblanc, Judith Landman Parker, Mathieu Simonin   +17 more
wiley   +1 more source

Dose‐dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy

British Journal of Haematology, EarlyView.
Prospective functional MRI brain and neurocognitive assessments were performed serially during intensive chemotherapy for a cohort of adults with newly diagnosed acute myeloid leukaemia to elucidate ‘chemobrain’ language phenomena. At completion of consolidation, significant reductions in functional and microstructural connectivity were observed ...
Ashleigh P. Scott, Ada Lo, Ying Xia, Kate Thompson, Harriet Bodimeade, Amir Fazlollahi, Nicholas Weber, Cameron Curley, Stewart Hunt, Kirk Morris, Caroline McNamara, Nilu Perera, Elango Subramoniapillai, Steven W. Lane, Glen A. Kennedy, Olivier Salvado, Javier Urriola, Katie L. McMahon   +17 more
wiley   +1 more source

Methotrexate and Cytarabine—Loaded Nanocarriers for Multidrug Cancer Therapy. Spectroscopic Study

Molecules, 2016
Determining the properties of nanoparticles obtained by novel methods and defining the scope of their application as drug carriers has important practical significance.
Danuta Pentak, Violetta Kozik, Andrzej Bąk, Paulina Dybał, Aleksander Sochanik, Josef Jampilek   +5 more
doaj   +1 more source

Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes

British Journal of Haematology, EarlyView.
Multivariable‐adjusted associations between family history of haematological malignancy (FHHM) and survival outcomes by non‐Hodgkin lymphoma subtype [OS (A), EFS (B), LSS (C) and failure to achieve EFS at 24 months (D)]. Subtype‐specific analyses showed that FHHM was associated with significantly inferior EFS in MCL and inferior LSS in FL.
George A. Cholack, Raphael Mwangi, Prokop Vodička, Thomas M. Habermann, Verena Hinder, Dennis P. Robinson, Andrew L. Feldman, Thomas E. Witzig, Jose C. Villasboas, Stephen M. Ansell, Brian K. Link, Yucai Wang, Carrie A. Thompson, Susan L. Slager, Matthew Maurer, Anne J. Novak, James R. Cerhan   +16 more
wiley   +1 more source

Frontline ATRA‐ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG‐APL2017 Trial

Cancer Science, EarlyView.
FBMTG‐APL2017: First prospective multicenter trial evaluating frontline ATRA‐ATO therapy for newly diagnosed APL in Japan, encompassing both low–intermediate (n = 65) and high‐risk (n = 16) patients. Excellent outcomes (95% CR, 94% 3‐year DFS) with comparable efficacy between risk groups (DFS: 97% vs.
Ken Takase, Tomohiko Kamimura, Takuro Kuriyama, Takahito Tokuyama, Hideho Henzan, Yoshikane Kikushige, Ilseung Choi, Yutaka Imamura, Akio Mori, Shuki Ohya, Noriaki Kawano, Koji Yonemoto, Mine Harada, Koichi Akashi, Toshihiro Miyamoto   +14 more
wiley   +1 more source